NCT00729963View on ClinicalTrials.gov

Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Obstructive Sleep ApneaObesityHypertension
Interventions
DRUG

Sibutramine

The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.

DEVICE

CPAP

All Listed Sponsors
lead

Laval University

OTHER

NCT00729963 - Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients | Biotech Hunter | Biotech Hunter